Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.10.0.1
Stockholders' Equity
6 Months Ended
Jun. 30, 2018
Stockholders Equity Note [Abstract]  
Stockholders Equity Note Disclosure [Text Block]
9.
Stockholders’ Equity
 
Stock-Based Compensation
 
On May 7, 2018, in connection with the closing of the sale under the APA of substantially all of the Company’s assets to Cellularity, which triggered certain change in control provisions of the Company’s equity plans, all unvested and outstanding options and restricted stock awards under the 2011 Plan and 2014 Plan became vested and exercisable.
 
As a result, a summary of the Company’s outstanding and exercisable options as of June 30, 2018 was as follows (in thousands, except per share data):
 
 
 
Options Outstanding
 
Options Exercisable
 
 
 
 
Range of
Exercise Price
 
Weighted
Average
Exercise
Price
 
Outstanding
Number of
Options
 
Weighted Average
Exercise Price
 
Weighted
Average
Remaining
Life in Years
 
Exercisable
Number of
Options
 
$2.00 - $4.00
 
$
3.51
 
 
215
 
 
3.51
 
 
2.3
 
 
215
 
$4.10 - $9.90
 
 
8.53
 
 
28
 
 
8.53
 
 
6.3
 
 
28
 
$10.00 - $19.90
 
 
10.57
 
 
76
 
 
10.57
 
 
1.2
 
 
76
 
$20.00 - $29.90
 
 
23.80
 
 
1
 
 
23.80
 
 
0.1
 
 
1
 
$30.00 - $39.90
 
 
33.63
 
 
46
 
 
33.63
 
 
4.3
 
 
46
 
$40.00 - $49.90
 
 
46.34
 
 
69
 
 
46.34
 
 
1.7
 
 
69
 
$50.00 - $59.90
 
 
52.92
 
 
43
 
 
52.92
 
 
1.1
 
 
43
 
$60.00 - $69.90
 
 
66.09
 
 
176
 
 
66.09
 
 
3.4
 
 
176
 
$70.00 - $79.90
 
 
77.54
 
 
3
 
 
77.54
 
 
1.2
 
 
3
 
$80.00 - $89.90
 
 
87.18
 
 
23
 
 
87.18
 
 
1.7
 
 
23
 
$90.00 - $99.90
 
 
90.04
 
 
21
 
 
90.04
 
 
1.8
 
 
21
 
$100.00 - $266.90
 
 
109.49
 
 
6
 
 
109.49
 
 
1.8
 
 
6
 
 
 
 
 
 
 
707
 
 
 
 
 
2.6
 
 
707
 
 
For the three months ended June 30, 2018 and 2017, the Company recognized $1.0 million and $0.4 million of stock-based compensation expense, of which, $0.009 million and $0.015 million is included in cost of revenues and $1.0 million and $0.4 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. For the six months ended June 30, 2018 and 2017, the Company recognized $0.9 million and $0.9 million of stock-based compensation expense, of which, $0.02 million and $0.026 million is included in cost of revenues and $0.9 million and $0.9 million is included in selling, general and administrative expenses in the condensed consolidated statements of operations, respectively. As of June 30, 2018, there was $0.02 million of unrecognized stock-based compensation expense which will be amortized over a weighted average period of 0.3 years.
 
Reverse Stock Split
 
The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share.